Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC LAWITZ

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1578661716
CMS profile
207873
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$164,148.34

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC LAWITZ

NPI 1578661716 · CMS profile ID 207873

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $164,148.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $451.0204/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248795 CMS
AbbVie, Inc. $64.3104/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248799 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7,777.5004/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749863421 CMS
Dova Pharmaceuticals $3,750.0004/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705226845 CMS
Dova Pharmaceuticals $258.6004/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705228091 CMS
Dova Pharmaceuticals $119.6304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705229481 CMS
Dova Pharmaceuticals $75.6904/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705230731 CMS
Gilead Sciences, Inc. $670.0004/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679260479 CMS
Gilead Sciences, Inc. $15.6904/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549097 CMS
Intercept Pharmaceuticals, Inc. $500.0004/17/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702089047 CMS
PFIZER INC. $19.6604/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124530 CMS
Gilead Sciences, Inc. $83.5304/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549095 CMS
Dova Pharmaceuticals $14.0104/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705236849 CMS
Merck Sharp & Dohme Corporation $63.5104/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695887497 CMS
E.R. Squibb & Sons, L.L.C. $48.7204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651280081 CMS
E.R. Squibb & Sons, L.L.C. $27.2504/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651280083 CMS
AbbVie, Inc. $1,250.0003/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248781 CMS
Siemens Medical Solutions USA, Inc. $50.0003/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943681 CMS
Gilead Sciences, Inc. $13.4103/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549093 CMS
Intercept Pharmaceuticals, Inc. $124.9903/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702089039 CMS
Intercept Pharmaceuticals, Inc. $3,400.0003/19/2019 Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702089043 CMS
Siemens Medical Solutions USA, Inc. $6,250.0003/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943675 CMS
Siemens Medical Solutions USA, Inc. $44.8702/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943685 CMS
Siemens Medical Solutions USA, Inc. $317.8602/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943701 CMS
Gilead Sciences, Inc. $14.3802/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679347587 CMS
Gilead Sciences, Inc. $50.0002/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679347589 CMS
Gilead Sciences, Inc. $8.5602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549091 CMS
Gilead Sciences, Inc. $13.5002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549089 CMS
Gilead Sciences, Inc. $3,720.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679312333 CMS
Gilead Sciences, Inc. $250.0002/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679347575 CMS
Gilead Sciences, Inc. $354.0002/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679347583 CMS
Gilead Sciences, Inc. $582.9802/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679347585 CMS
Gilead Sciences, Inc. $43.7002/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549083 CMS
Gilead Sciences, Inc. $49.9802/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549085 CMS
Gilead Sciences, Inc. $119.9802/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681549087 CMS
Siemens Medical Solutions USA, Inc. $330.2602/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943689 CMS
Siemens Medical Solutions USA, Inc. $9.0002/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631943692 CMS
AbbVie, Inc. $67.9802/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248759 CMS
Intercept Pharmaceuticals, Inc. $500.0002/05/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702089033 CMS
AbbVie, Inc. $4,375.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248745 CMS
AbbVie, Inc. $4,375.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248753 CMS
AbbVie, Inc. $4,375.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248761 CMS
AbbVie, Inc. $404.0001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248739 CMS
AbbVie, Inc. $17.6301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248763 CMS
AbbVie, Inc. $150.7001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248765 CMS
AbbVie, Inc. $17.3201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248741 CMS
AbbVie, Inc. $108.4101/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248743 CMS
AbbVie, Inc. $297.2901/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248749 CMS
AbbVie, Inc. $382.2301/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248757 CMS
AbbVie, Inc. $127.3401/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648248747 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $164,148.34 155
PY2020 $56,978.64 43
PY2021 $61,211.70 51
PY2022 $46,146.23 38
PY2023 $106,237.71 54
PY2024 $135,448.87 103
PY2025 $206,113.22 120

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $306.91 7
PY2025 Principal investigator $11,657,092.67 1,309
PY2024 Recipient $5,977.17 18
PY2024 Principal investigator $8,383,016.22 257
PY2023 Recipient $29,294.75 36
PY2023 Principal investigator $9,948,237.96 366
PY2022 Recipient $412.01 3
PY2022 Principal investigator $6,740,494.10 397
PY2021 Recipient $249.50 1
PY2021 Principal investigator $5,223,910.82 847
PY2020 Recipient $10,691.56 1
PY2020 Principal investigator $8,262,804.27 280
PY2019 Recipient $1,913.39 3
PY2019 Principal investigator $8,493,525.14 307

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,316 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/31/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783133
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 12/31/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783135
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 12/31/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783137
Principal investigator 1 Boehringer Ingelheim International GmbH $492.00 12/31/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783139
Principal investigator 1 Exelixis Inc. $43,266.90 12/30/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379584
Principal investigator 1 F. Hoffmann-La Roche AG $6,686.25 12/29/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572750
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783037
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783039
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783041
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783043
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783045
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783047
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783049
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783051
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783053
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783055
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783057
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783059
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783061
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783063
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783065
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783067
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783069
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783071
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783073
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783075
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783077
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783079
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783081
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783083
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783085
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783087
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783089
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783091
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 12/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783093
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 12/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782619
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782621
Principal investigator 1 Genentech, Inc. $26,114.00 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572652
Principal investigator 1 Ipsen Bioscience Inc. $29,666.25 12/19/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546757
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118264
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118268
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118272
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118275
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118279
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118284
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118286
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118290
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118295
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118299
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118305
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118310
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118314
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118318
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118323
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118329
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118333
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118336
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118341
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118344
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118348
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 12/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118352
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 12/18/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783141
Principal investigator 1 Boehringer Ingelheim International GmbH $158.35 12/18/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783143
Principal investigator 1 Boehringer Ingelheim International GmbH $186.56 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782731
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782733
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782735
Principal investigator 1 Boehringer Ingelheim International GmbH $252.20 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782737
Principal investigator 1 Boehringer Ingelheim International GmbH $156.32 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782739
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782761
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782763
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782765
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782767
Principal investigator 1 Boehringer Ingelheim International GmbH $234.00 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783145
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783147
Principal investigator 1 Boehringer Ingelheim International GmbH $283.00 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) No dispute reported 06/30/2026 1220783149
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $466.40 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999037
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $244.28 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999039
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.48 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999041
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $222.72 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999043
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.36 12/17/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999045
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187874697
Principal investigator 1 Eli Lilly and Company $1,395.66 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187874997
Principal investigator 1 Genentech, Inc. $6,453.00 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572648
Principal investigator 1 Genentech, Inc. $218.57 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572894
Principal investigator 1 Genentech, Inc. $8,505.00 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572899
Principal investigator 1 GlaxoSmithKline, LLC. $850.00 12/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192163087
Principal investigator 1 Ipsen Pharma SAS $257.40 12/17/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306831
Principal investigator 1 Eli Lilly and Company $313.03 12/16/2025 Non-covered Recipient Entity
THE TEXAS LIVER INSTITUTE
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA No dispute reported 06/30/2026 1187891904
Principal investigator 1 F. Hoffmann-La Roche AG $62,100.00 12/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572760
Principal investigator 1 Boehringer Ingelheim International GmbH $69.30 12/12/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781864
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 12/12/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781868
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 12/12/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781872
Principal investigator 1 Deciphera Pharmaceuticals Inc. $84,729.39 12/11/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS No dispute reported 06/30/2026 1235976889
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,108.52 12/11/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS No dispute reported 06/30/2026 1235976892
Principal investigator 1 Genentech, Inc. $296.00 12/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572661
Principal investigator 1 GlaxoSmithKline, LLC. $4,684.50 12/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192166436
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253794
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223289522
Principal investigator 1 Intercept Pharmaceuticals, Inc. $9,644.68 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171134
Principal investigator 1 Ipsen Bioscience Inc. $11,569.50 12/04/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,013.70 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269121
Principal investigator 1 X4 Pharmaceuticals, Inc. $150.00 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118158
Principal investigator 1 X4 Pharmaceuticals, Inc. $348.30 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118161
Principal investigator 1 X4 Pharmaceuticals, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118165
Principal investigator 1 X4 Pharmaceuticals, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118169
Principal investigator 1 X4 Pharmaceuticals, Inc. $348.30 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118172
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118177
Principal investigator 1 X4 Pharmaceuticals, Inc. $150.00 12/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253118180
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 12/03/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781866
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 12/03/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781870
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 12/03/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783035
Principal investigator 1 Genentech, Inc. $4,608.00 12/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572656
Principal investigator 1 Genentech, Inc. $41.58 12/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572665
Principal investigator 1 Exelixis Inc. $1,650.00 12/02/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379578
Principal investigator 1 F. Hoffmann-La Roche AG $4,610.25 12/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572755
Principal investigator 1 F. Hoffmann-La Roche AG $73.93 12/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572764
Principal investigator 1 GlaxoSmithKline, LLC. $14,053.50 12/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192110119
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781834
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781836
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781838
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781840
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781842
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781844
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781846
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781848
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781850
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781852
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781854
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781856
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781858
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 11/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781860
Principal investigator 1 Madrigal Pharmaceuticals $1,150.50 11/27/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253125
Principal investigator 1 Ipsen Bioscience Inc. $55,552.50 11/25/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546741
Principal investigator 1 Genentech, Inc. $1,875.00 11/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572882
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782981
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782983
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782985
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782987
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782989
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782991
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782993
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782995
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782997
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782999
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783001
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783003
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783005
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783007
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783009
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783011
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783013
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783015
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783017
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783019
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783021
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783023
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783025
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783027
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783029
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783031
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 11/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220783033
Principal investigator 1 Genentech, Inc. $76.02 11/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572853
Principal investigator 1 Genentech, Inc. $9,609.00 11/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572857
Principal investigator 1 Genentech, Inc. $77,281.00 11/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572861
Principal investigator 1 Genentech, Inc. $214.42 11/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572866
Principal investigator 1 Ipsen Bioscience Inc. $2,673.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546673
Principal investigator 1 Ipsen Bioscience Inc. $439.43 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546675
Principal investigator 1 Ipsen Bioscience Inc. $573.75 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546677
Principal investigator 1 Ipsen Bioscience Inc. $95.76 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546679
Principal investigator 1 Ipsen Bioscience Inc. $891.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546681
Principal investigator 1 Ipsen Bioscience Inc. $300.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546683
Principal investigator 1 Ipsen Bioscience Inc. $891.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546685
Principal investigator 1 Ipsen Bioscience Inc. $891.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546687
Principal investigator 1 Ipsen Bioscience Inc. $750.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546689
Principal investigator 1 Ipsen Bioscience Inc. $891.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546691
Principal investigator 1 Ipsen Bioscience Inc. $2,814.49 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546693
Principal investigator 1 Ipsen Bioscience Inc. $300.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546695
Principal investigator 1 Ipsen Bioscience Inc. $142.57 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546697
Principal investigator 1 Ipsen Bioscience Inc. $750.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546699
Principal investigator 1 Ipsen Bioscience Inc. $750.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546701
Principal investigator 1 Ipsen Bioscience Inc. $2,673.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546731
Principal investigator 1 Ipsen Bioscience Inc. $300.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546733
Principal investigator 1 Ipsen Bioscience Inc. $891.00 11/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546735
Principal investigator 1 Boehringer Ingelheim International GmbH $929.20 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781892
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782725
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782727
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782729
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782757
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782759
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782975
Principal investigator 1 Boehringer Ingelheim International GmbH $1,700.00 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782977
Principal investigator 1 Boehringer Ingelheim International GmbH $810.00 11/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782979
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $105.00 11/19/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818685
Principal investigator 1 Genentech, Inc. $35.87 11/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572845
Principal investigator 1 Genentech, Inc. $60,446.00 11/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572870
Principal investigator 1 Genentech, Inc. $42,483.00 11/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572874
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 11/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163111
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 11/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223288543
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $72,433.00 11/18/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818683
Principal investigator 1 GlaxoSmithKline, LLC. $21,082.94 11/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192166444
Principal investigator 1 Genentech, Inc. $5,304.00 11/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572890
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,750.00 11/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171136
Principal investigator 1 Ipsen Bioscience Inc. $5,494.50 11/14/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546713
Principal investigator 1 Ipsen Pharma SAS $4,386.00 11/14/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306999
Principal investigator 1 Madrigal Pharmaceuticals $6,740.50 11/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252637
Principal investigator 1 Madrigal Pharmaceuticals $750.00 11/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,039.55 11/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $59.64 11/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223288355
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,350.00 11/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171132
Principal investigator 1 Boehringer Ingelheim International GmbH $69.30 11/12/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781862
Principal investigator 1 Genentech, Inc. $76.02 11/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572849
Principal investigator 1 Genentech, Inc. $4,171.50 11/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572878
Principal investigator 1 GlaxoSmithKline, LLC. $131.95 11/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192166440
Principal investigator 1 Genentech, Inc. $29,295.00 11/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572887
Principal investigator 1 GlaxoSmithKline, LLC. $11,996.31 11/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166804
Principal investigator 1 Ipsen Bioscience Inc. $58,792.50 11/07/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,111.60 11/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258887
Principal investigator 1 Ipsen Pharma SAS $514.80 11/05/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306827
Principal investigator 1 Ipsen Pharma SAS $4,233.60 11/05/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306829
Principal investigator 1 PTC Therapeutics, Inc. $600.00 11/05/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093770
Principal investigator 1 F. Hoffmann-La Roche AG $15,925.80 11/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572746
Principal investigator 1 GlaxoSmithKline, LLC. $18,485.06 11/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192110126
Principal investigator 1 H. Lundbeck A S $3,000.00 11/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
Hepatic Impairment Study No dispute reported 06/30/2026 1251776523
Principal investigator 1 PTC Therapeutics, Inc. $3,908.25 11/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093768
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,683.88 11/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223287885
Principal investigator 1 X4 Pharmaceuticals, Inc. $150.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117931
Principal investigator 1 X4 Pharmaceuticals, Inc. $500.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117935
Principal investigator 1 X4 Pharmaceuticals, Inc. $150.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117940
Principal investigator 1 X4 Pharmaceuticals, Inc. $150.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117943
Principal investigator 1 X4 Pharmaceuticals, Inc. $500.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117948
Principal investigator 1 X4 Pharmaceuticals, Inc. $500.00 10/30/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117952
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48.72 10/29/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818679
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $367,204.00 10/28/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818677
Principal investigator 1 Gilead Sciences, Inc. $8,638.23 10/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203783
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781874
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781876
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781878
Principal investigator 1 Boehringer Ingelheim International GmbH $131.10 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781880
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781882
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781884
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781886
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781888
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781890
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782719
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782721
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782723
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 10/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783131
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48.72 10/27/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818675
Principal investigator 1 X4 Pharmaceuticals, Inc. $11,005.20 10/27/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117927
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,203.00 10/23/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818673
Principal investigator 1 Intercept Pharmaceuticals, Inc. $675.00 10/23/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171130
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782955
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782957
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782959
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782961
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782963
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782965
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782967
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782969
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782971
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/22/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782973
Principal investigator 1 GlaxoSmithKline, LLC. $4,684.50 10/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192166800
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,908.71 10/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223287201
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,957.50 10/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223287235
Principal investigator 1 Genentech, Inc. $40,335.00 10/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572832
Principal investigator 1 Genentech, Inc. $3,656.00 10/17/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
CPET No dispute reported 06/30/2026 1211603528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $810.00 10/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223287125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,233.40 10/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250493
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782605
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782607
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782609
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782611
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782613
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782615
Principal investigator 1 Boehringer Ingelheim International GmbH $6,000.00 10/15/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782617
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,093.25 10/14/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818671
Principal investigator 1 Exelixis Inc. $38,138.25 10/14/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379572
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 10/08/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781832
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/06/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782793
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 10/06/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782795
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.37 10/06/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818668
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $602.99 10/03/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,543.35 10/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244539
Principal investigator 1 Boehringer Ingelheim International GmbH $253.04 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782797
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782799
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782801
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782803
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782805
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782807
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782809
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782811
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782813
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782815
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782817
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782819
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782821
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782823
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782825
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782827
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782829
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782831
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782833
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782835
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782837
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782839
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782841
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782843
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782845
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782847
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782849
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782851
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782853
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782855
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782857
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782859
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782861
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782863
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782865
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782867
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782869
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782871
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782873
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782875
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782877
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782879
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782881
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782883
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782885
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782887
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782889
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782891
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782893
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782895
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782897
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782899
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782901
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782903
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782905
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782907
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782909
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782911
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782913
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782915
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782917
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782919
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782921
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782923
Principal investigator 1 Boehringer Ingelheim International GmbH $5,778.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782925
Principal investigator 1 Boehringer Ingelheim International GmbH $4,516.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782927
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782929
Principal investigator 1 Boehringer Ingelheim International GmbH $3,841.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782931
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782933
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782935
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782937
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782939
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782941
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782943
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782945
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782947
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782949
Principal investigator 1 Boehringer Ingelheim International GmbH $3,443.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782951
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 10/02/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782953
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $17,000.00 10/01/2025 Non-covered Recipient Entity
Centricity Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220812222
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $63.51 10/01/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818664
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,743.15 10/01/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818666
Principal investigator 1 Genentech, Inc. $17,200.00 10/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572836
Principal investigator 1 Genentech, Inc. $13,824.00 10/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib No dispute reported 06/30/2026 1211572841
Principal investigator 1 H. Lundbeck A S $25,100.00 10/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
Hepatic Impairment Study No dispute reported 06/30/2026 1251775125
Principal investigator 1 Exelixis Inc. $10,359.87 09/30/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379574
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781796
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781798
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781800
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781802
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781804
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781806
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781808
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781810
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781812
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781814
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781816
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781818
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781820
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781824
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781826
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781828
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 09/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781830
Principal investigator 1 GlaxoSmithKline, LLC. $4,477.77 09/25/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192170018
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783119
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783121
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783123
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783125
Principal investigator 1 Boehringer Ingelheim International GmbH $3.33 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783127
Principal investigator 1 Boehringer Ingelheim International GmbH $7.56 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783129
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.66 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999033
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.32 09/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999035
Principal investigator 1 Genentech, Inc. $71.74 09/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572794
Principal investigator 1 Genentech, Inc. $81,625.00 09/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572798
Principal investigator 1 Genentech, Inc. $16,303.00 09/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572807
Principal investigator 1 Genentech, Inc. $153.14 09/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572812
Principal investigator 1 Ipsen Bioscience Inc. $950.00 09/23/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546635
Principal investigator 1 Ipsen Bioscience Inc. $3,543.00 09/23/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546637
Principal investigator 1 PTC Therapeutics, Inc. $3,908.25 09/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093673
Principal investigator 1 Boehringer Ingelheim International GmbH $1,823.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782769
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782771
Principal investigator 1 Boehringer Ingelheim International GmbH $950.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782773
Principal investigator 1 Boehringer Ingelheim International GmbH $3,700.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782775
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782777
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782779
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782781
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782783
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782785
Principal investigator 1 Boehringer Ingelheim International GmbH $4,536.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782787
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782789
Principal investigator 1 Boehringer Ingelheim International GmbH $3,308.00 09/19/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220782791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 09/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184240824
Principal investigator 1 GlaxoSmithKline, LLC. $22,300.00 09/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV No dispute reported 06/30/2026 1192166448
Principal investigator 1 GlaxoSmithKline, LLC. $14,152.38 09/15/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192170031
Principal investigator 1 Ipsen Pharma SAS $380.00 09/12/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.10 09/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236522
Principal investigator 1 GlaxoSmithKline, LLC. $506.25 09/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192110109
Principal investigator 1 GlaxoSmithKline, LLC. $29,481.88 09/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192163092
Principal investigator 1 GlaxoSmithKline, LLC. $1,518.75 09/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192166790
Principal investigator 1 Grifols Shared Services North America, Inc. $33,439.85 09/10/2025 Non-covered Recipient Entity
American Research Corporation
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167927
Principal investigator 1 Boehringer Ingelheim International GmbH $12,636.00 09/08/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783169
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782485
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782487
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782489
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782491
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782493
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782495
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782497
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782499
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782501
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782503
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782505
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782507
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782509
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782511
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782513
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782515
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782517
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782519
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782521
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782523
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782525
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782527
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782529
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782531
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782533
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782535
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782537
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782539
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782541
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782543
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782545
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782547
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782549
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782551
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782553
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782555
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782557
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782559
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782561
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782563
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782565
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782567
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782569
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782571
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782573
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782575
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782577
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782579
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782581
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782583
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782585
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782587
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782589
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782591
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782593
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782595
Principal investigator 1 Boehringer Ingelheim International GmbH $1,215.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782597
Principal investigator 1 Boehringer Ingelheim International GmbH $6,474.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782599
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782601
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 09/05/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782603
Principal investigator 1 Madrigal Pharmaceuticals $3,065.40 09/05/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249794
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,302.15 09/05/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223285161
Principal investigator 1 Genentech, Inc. $36,400.00 09/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572828
Principal investigator 1 GlaxoSmithKline, LLC. $3,358.26 09/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192110102
Principal investigator 1 Exelixis Inc. $1,009.37 09/02/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379590
Principal investigator 1 Genentech, Inc. $9,830.00 09/02/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB No dispute reported 06/30/2026 1211601454
Principal investigator 1 GlaxoSmithKline, LLC. $337.50 09/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192166432
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $654.75 09/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223284749
Principal investigator 1 Boehringer Ingelheim International GmbH $69.30 09/01/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781822
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781708
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781710
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781712
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781714
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781716
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781718
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781720
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781722
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781724
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781726
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781728
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781730
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781732
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781734
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781736
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781738
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781740
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781742
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781744
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781746
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781748
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781750
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781752
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781754
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781756
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781758
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781760
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781762
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781764
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781766
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781768
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 08/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781770
Principal investigator 1 PTC Therapeutics, Inc. $29,390.83 08/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093619
Principal investigator 1 Gilead Sciences, Inc. $21,868.37 08/27/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) No dispute reported 06/30/2026 1229203000
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783107
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783109
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783111
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783113
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783115
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783117
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $513.04 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999023
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $244.28 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999025
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.48 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999027
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $232.00 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999029
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.36 08/26/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999031
Principal investigator 1 Exelixis Inc. $1,502.92 08/26/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379576
Principal investigator 1 Exelixis Inc. $35.87 08/26/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379580
Principal investigator 1 Gilead Sciences, Inc. $600.00 08/26/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203766
Principal investigator 1 Genentech, Inc. $8,215.69 08/20/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572802
Principal investigator 1 Eli Lilly and Company $159,153.56 08/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP INC
A PHASE 1, MULTICENTER, PARALLEL-DESIGN, SINGLE-DOSE, OPEN-LABEL STUDY OF LEPODISIRAN IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1187874457
Principal investigator 1 Madrigal Pharmaceuticals $9,041.50 08/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248791
Principal investigator 1 GlaxoSmithKline, LLC. $425.25 08/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163107
Principal investigator 1 GlaxoSmithKline, LLC. $425.25 08/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166428
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,025.00 08/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171128
Principal investigator 1 Ipsen Pharma SAS $5,987.25 08/14/2025 Non-covered Recipient Entity
American Research Corporation
A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity No dispute reported 06/30/2026 1184306825
Principal investigator 1 ABBVIE INC. $2,430.00 08/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine No dispute reported 06/30/2026 1202504511
Principal investigator 1 ABBVIE INC. $15,902.91 08/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine No dispute reported 06/30/2026 1202504527
Principal investigator 1 ABBVIE INC. $4,462.20 08/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine No dispute reported 06/30/2026 1202504529
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 08/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572720
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 08/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572733
Principal investigator 1 GlaxoSmithKline, LLC. $5,792.52 08/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166823
Principal investigator 1 PTC Therapeutics, Inc. $11,724.75 08/08/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093595
Principal investigator 1 PTC Therapeutics, Inc. $47.04 08/08/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093597
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 08/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782481
Principal investigator 1 Boehringer Ingelheim International GmbH $1,020.00 08/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782483
Principal investigator 1 Ipsen Pharma SAS $16,659.00 08/07/2025 Non-covered Recipient Entity
American Research Corporation
A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity No dispute reported 06/30/2026 1184306823
Principal investigator 1 Ipsen Pharma SAS $2,374.20 08/06/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306819
Principal investigator 1 Ipsen Pharma SAS $1,464.00 08/06/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306821
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117758
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117762
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117766
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117770
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117774
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117778
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117783
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117787
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117792
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117797
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117800
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117805
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117811
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117815
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117819
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117823
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117827
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117830
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 08/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117834
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $41,553.20 08/01/2025 Non-covered Recipient Entity
American Research Corporation
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis No dispute reported 06/30/2026 1220818691
Principal investigator 1 Genentech, Inc. $1,123.16 08/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.70 08/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223283571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $202.50 08/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223283573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,136.80 08/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223283575
Principal investigator 1 Ipsen Bioscience Inc. $9,497.25 07/31/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546593
Principal investigator 1 Exelixis Inc. $465.30 07/30/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379582
Principal investigator 1 Exelixis Inc. $1,066.82 07/30/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379586
Principal investigator 1 Boehringer Ingelheim International GmbH $4,646.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781772
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781774
Principal investigator 1 Boehringer Ingelheim International GmbH $459.54 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781776
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781778
Principal investigator 1 Boehringer Ingelheim International GmbH $916.05 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781780
Principal investigator 1 Boehringer Ingelheim International GmbH $437.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781782
Principal investigator 1 Boehringer Ingelheim International GmbH $2.70 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781784
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781786
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781788
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781790
Principal investigator 1 Boehringer Ingelheim International GmbH $25.35 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781792
Principal investigator 1 Boehringer Ingelheim International GmbH $117.50 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781794
Principal investigator 1 Boehringer Ingelheim International GmbH $433.87 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782367
Principal investigator 1 Boehringer Ingelheim International GmbH $87.67 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782369
Principal investigator 1 Boehringer Ingelheim International GmbH $38.87 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782371
Principal investigator 1 Boehringer Ingelheim International GmbH $2,065.50 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782453
Principal investigator 1 Boehringer Ingelheim International GmbH $1,032.75 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782455
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782457
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782459
Principal investigator 1 Boehringer Ingelheim International GmbH $336.08 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782461
Principal investigator 1 Boehringer Ingelheim International GmbH $313.07 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782463
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782465
Principal investigator 1 Boehringer Ingelheim International GmbH $293.62 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782467
Principal investigator 1 Boehringer Ingelheim International GmbH $209.75 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782469
Principal investigator 1 Boehringer Ingelheim International GmbH $138.22 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782471
Principal investigator 1 Boehringer Ingelheim International GmbH $118.86 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782473
Principal investigator 1 Boehringer Ingelheim International GmbH $95.76 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782475
Principal investigator 1 Boehringer Ingelheim International GmbH $68.88 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782477
Principal investigator 1 Boehringer Ingelheim International GmbH $35.87 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782479
Principal investigator 1 Boehringer Ingelheim International GmbH $12.24 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782707
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782709
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782711
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782713
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782715
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782717
Principal investigator 1 Boehringer Ingelheim International GmbH $12.24 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782745
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782747
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782749
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782751
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782753
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782755
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783095
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783097
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783099
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783101
Principal investigator 1 Boehringer Ingelheim International GmbH $1.85 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783103
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 07/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220783105
Principal investigator 1 PTC Therapeutics, Inc. $18,358.63 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093585
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117281
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117284
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117288
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117292
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117296
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117301
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117303
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,056.10 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117307
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,151.95 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117312
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117317
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,806.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117320
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,968.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117324
Principal investigator 1 X4 Pharmaceuticals, Inc. $6,853.95 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117328
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,342.60 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117332
Principal investigator 1 X4 Pharmaceuticals, Inc. $654.75 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117336
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,502.60 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117340
Principal investigator 1 X4 Pharmaceuticals, Inc. $4,538.70 07/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117345
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,935.75 07/25/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223283184
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,188.78 07/25/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223283202
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782685
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782687
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782689
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782691
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782693
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782695
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782697
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782699
Principal investigator 1 Boehringer Ingelheim International GmbH $139.31 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782701
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782703
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220782705
Principal investigator 1 Boehringer Ingelheim International GmbH $170.80 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782741
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 07/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220782743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,000.00 07/22/2025 Non-covered Recipient Entity
American Research Corporation
Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220818662
Principal investigator 1 Ipsen Bioscience Inc. $2,747.25 07/22/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546591
Principal investigator 1 Gilead Sciences, Inc. $992.40 07/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203776
Principal investigator 1 Ipsen Bioscience Inc. $17,043.75 07/17/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 07/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217020
Principal investigator 1 Genentech, Inc. $1,701.00 07/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572816
Principal investigator 1 F. Hoffmann-La Roche AG $2,936.25 07/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572724
Principal investigator 1 GlaxoSmithKline, LLC. $1,569.15 07/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192110130
Principal investigator 1 GlaxoSmithKline, LLC. $20,221.30 07/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192163115
Principal investigator 1 GlaxoSmithKline, LLC. $7,261.15 07/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166794
Principal investigator 1 Ipsen Bioscience Inc. $67,142.25 07/10/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546587
Principal investigator 1 Exelixis Inc. $1,883.25 07/08/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379588
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782373
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782375
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782377
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782379
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782381
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782383
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782385
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782387
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782389
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782391
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782393
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782395
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782397
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782399
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782401
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782403
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782405
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782407
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782409
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782411
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782413
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782415
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782417
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782419
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782421
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782423
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782425
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782427
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782429
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782431
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782433
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782435
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782437
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782439
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782441
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782443
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782445
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782447
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782449
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 07/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782451
Principal investigator 1 F. Hoffmann-La Roche AG $1,674.00 07/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $654.75 07/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223282386
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 07/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781704
Principal investigator 1 Boehringer Ingelheim International GmbH $207.90 07/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781706
Principal investigator 1 Ipsen Bioscience Inc. $9,497.25 07/04/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546585
Principal investigator 1 Ipsen Pharma SAS $5,835.60 07/04/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306815
Principal investigator 1 Ipsen Pharma SAS $2,324.10 07/04/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306817
Principal investigator 1 Ipsen Pharma SAS $4,006.00 07/04/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 07/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212741
Principal investigator 1 Genentech, Inc. $5,029.52 07/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572819
Principal investigator 1 F. Hoffmann-La Roche AG $1,875.00 07/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572729
Principal investigator 1 F. Hoffmann-La Roche AG $12,514.50 07/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572737
Principal investigator 1 F. Hoffmann-La Roche AG $2,626.35 07/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572741
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 06/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781584
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 06/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781626
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 06/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781632
Principal investigator 1 Boehringer Ingelheim International GmbH $369.30 06/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781650
Principal investigator 1 Boehringer Ingelheim International GmbH $69.30 06/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781624
Principal investigator 1 GlaxoSmithKline, LLC. $43,783.74 06/25/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA No dispute reported 06/30/2026 1192170036
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781542
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781544
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781546
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781548
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781550
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781552
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781554
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781556
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781558
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781560
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781562
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781564
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781566
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781568
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781570
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781572
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781574
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781576
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781578
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781580
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781582
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781586
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781588
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781590
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781592
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781594
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781596
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781598
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781602
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781604
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781606
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781608
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781610
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781612
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781614
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781616
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781618
Principal investigator 1 Boehringer Ingelheim International GmbH $6,241.05 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781620
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781622
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781628
Principal investigator 1 Boehringer Ingelheim International GmbH $3,782.70 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781630
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781634
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781636
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781638
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781640
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781642
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781644
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781646
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781648
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781652
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781654
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781656
Principal investigator 1 Boehringer Ingelheim International GmbH $2,886.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781658
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781660
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781662
Principal investigator 1 Boehringer Ingelheim International GmbH $1,501.20 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781664
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781666
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781668
Principal investigator 1 Boehringer Ingelheim International GmbH $2,103.30 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781670
Principal investigator 1 Boehringer Ingelheim International GmbH $3,709.80 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781672
Principal investigator 1 Boehringer Ingelheim International GmbH $5,147.55 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781674
Principal investigator 1 Boehringer Ingelheim International GmbH $1,602.45 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781676
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $711.26 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999013
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $366.42 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999015
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.22 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999017
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $336.40 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999019
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5.04 06/24/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants No dispute reported 06/30/2026 1220999021
Principal investigator 1 Exelixis Inc. $20,700.00 06/24/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment No dispute reported 06/30/2026 1222379570
Principal investigator 1 Ipsen Bioscience Inc. $2,931.70 06/24/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546579
Principal investigator 1 Ipsen Bioscience Inc. $1,771.50 06/24/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546581
Principal investigator 1 F. Hoffmann-La Roche AG $1,755.00 06/23/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572697
Principal investigator 1 Genentech, Inc. $107,499.00 06/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.35 06/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184209131
Principal investigator 1 F. Hoffmann-La Roche AG $29,295.00 06/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572705
Principal investigator 1 Genentech, Inc. $16,231.52 06/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572783
Principal investigator 1 GlaxoSmithKline, LLC. $5,037.39 06/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166812
Principal investigator 1 Ipsen Bioscience Inc. $25,393.50 06/12/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546569
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,561.80 06/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA No dispute reported 06/30/2026 1185547143
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,049.28 06/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 No dispute reported 06/30/2026 1185547151
Principal investigator 1 Genentech, Inc. $333.00 06/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572787
Principal investigator 1 Boehringer Ingelheim International GmbH $6,268.00 06/09/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783167
Principal investigator 1 F. Hoffmann-La Roche AG $272.61 06/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572673
Principal investigator 1 F. Hoffmann-La Roche AG $1,059.75 06/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572682
Principal investigator 1 F. Hoffmann-La Roche AG $4,171.50 06/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572701
Principal investigator 1 Ipsen Bioscience Inc. $105,927.75 06/05/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 06/05/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204141
Principal investigator 1 ABBVIE INC. $83,982.60 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine No dispute reported 06/30/2026 1202490135
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,705.90 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA No dispute reported 06/30/2026 1185547155
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782295
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782297
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782299
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782301
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782303
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782305
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782307
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782309
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782311
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782313
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782315
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782317
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782319
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782321
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782323
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782325
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782327
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782329
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782331
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782333
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782335
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782337
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782339
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782341
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782343
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782345
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782347
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782349
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782351
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782353
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782355
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782357
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782359
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782361
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782363
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 06/04/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782365
Principal investigator 1 Ipsen Pharma SAS $1,859.40 06/04/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,067.83 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280696
Principal investigator 1 X4 Pharmaceuticals, Inc. $10,000.00 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117232
Principal investigator 1 X4 Pharmaceuticals, Inc. $2,000.00 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117235
Principal investigator 1 X4 Pharmaceuticals, Inc. $5,000.00 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117238
Principal investigator 1 X4 Pharmaceuticals, Inc. $3,700.00 06/04/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117242
Principal investigator 1 F. Hoffmann-La Roche AG $118.86 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572669
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572678
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572684
Principal investigator 1 F. Hoffmann-La Roche AG $10,000.00 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572688
Principal investigator 1 F. Hoffmann-La Roche AG $218,726.25 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572693
Principal investigator 1 F. Hoffmann-La Roche AG $8,700.00 06/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 No dispute reported 06/30/2026 1211572711
Principal investigator 1 Boehringer Ingelheim International GmbH $138.60 05/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781678
Principal investigator 1 Madrigal Pharmaceuticals $150.00 05/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244682
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.50 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781690
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781692
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781694
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781696
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781698
Principal investigator 1 Boehringer Ingelheim International GmbH $2.70 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781700
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/27/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781702
Principal investigator 1 Ipsen Bioscience Inc. $1,465.85 05/27/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546559
Principal investigator 1 Ipsen Bioscience Inc. $61,539.75 05/27/2025 Non-covered Recipient Entity
American Research Corporation
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose No dispute reported 06/30/2026 1176546561
Principal investigator 1 Ipsen Pharma SAS $6,544.00 05/23/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306993
Principal investigator 1 Ipsen Bioscience Inc. $14,826.98 05/22/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,377.45 05/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197553
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781927
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781929
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781931
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781933
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781935
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781937
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781939
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781941
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781943
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781945
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781947
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781949
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781951
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781953
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781955
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781957
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781959
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781961
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781963
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781965
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781967
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781969
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781971
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781973
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781975
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781977
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781979
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781981
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781983
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781985
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781987
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781989
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781991
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781993
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781995
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781997
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781999
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782001
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782003
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782005
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782007
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782009
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782011
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782013
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782015
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782017
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782019
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782021
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782023
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782025
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782027
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782029
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782031
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782033
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782035
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782037
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782039
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782041
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782043
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782045
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782047
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782049
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782051
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782053
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782055
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782057
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782059
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782061
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782063
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782065
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782067
Principal investigator 1 Boehringer Ingelheim International GmbH $4,009.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782069
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782071
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782073
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782075
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782077
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782079
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782081
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782083
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782085
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782087
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782089
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782091
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782093
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782095
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782097
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782099
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782101
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782103
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782105
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782107
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782109
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782111
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782113
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782115
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782117
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782119
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782121
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782123
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782125
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782127
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782129
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782131
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782133
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782135
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782137
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782139
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782141
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782143
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782145
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782147
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782149
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782151
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782153
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782155
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782157
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782159
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782161
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782163
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782165
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782167
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782169
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782171
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782173
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782175
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782177
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782179
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782181
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782183
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782185
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782187
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782189
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782191
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782193
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782195
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782197
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782199
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782201
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782203
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782205
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782207
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782209
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782211
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782213
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782215
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782217
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782219
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782221
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782223
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782225
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782227
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782229
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782231
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782233
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782235
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782237
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782239
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782241
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782243
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782245
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782247
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782249
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782251
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782253
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782255
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782257
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782259
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782261
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782263
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782265
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782267
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782269
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782271
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782273
Principal investigator 1 Boehringer Ingelheim International GmbH $4,002.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782275
Principal investigator 1 Boehringer Ingelheim International GmbH $3,213.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782277
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782279
Principal investigator 1 Boehringer Ingelheim International GmbH $2,639.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782281
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782283
Principal investigator 1 Boehringer Ingelheim International GmbH $2,085.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782285
Principal investigator 1 Boehringer Ingelheim International GmbH $3,894.75 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782287
Principal investigator 1 Boehringer Ingelheim International GmbH $6,581.25 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782289
Principal investigator 1 Boehringer Ingelheim International GmbH $4,401.00 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782291
Principal investigator 1 Boehringer Ingelheim International GmbH $3,442.50 05/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220782293
Principal investigator 1 PTC Therapeutics, Inc. $23,874.73 05/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.35 05/15/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194607
Principal investigator 1 Genentech, Inc. $4,878.75 05/14/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572779
Principal investigator 1 Grifols Shared Services North America, Inc. $555.00 05/14/2025 Non-covered Recipient Entity
American Research Corporation
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167449
Principal investigator 1 GlaxoSmithKline, LLC. $18,259.33 05/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163083
Principal investigator 1 PTC Therapeutics, Inc. $3,908.25 05/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093385
Principal investigator 1 PTC Therapeutics, Inc. $96.60 05/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093387
Principal investigator 1 Ipsen Bioscience Inc. $5,950.80 05/08/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546551
Principal investigator 1 Genentech, Inc. $2,451.70 05/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572791
Principal investigator 1 Ipsen Pharma SAS $4,233.60 05/07/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306811
Principal investigator 1 Gilead Sciences, Inc. $6,274.57 05/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203758
Principal investigator 1 Ipsen Bioscience Inc. $742.50 05/02/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546549
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,231.90 05/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223278794
Principal investigator 1 Boehringer Ingelheim International GmbH $438.60 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781530
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781532
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781534
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781536
Principal investigator 1 Boehringer Ingelheim International GmbH $4,186.35 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781538
Principal investigator 1 Boehringer Ingelheim International GmbH $838.50 04/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781540
Principal investigator 1 Ipsen Bioscience Inc. $3,779.10 04/28/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546541
Principal investigator 1 Ipsen Bioscience Inc. $1,996.22 04/28/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546545
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 04/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781680
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781682
Principal investigator 1 Boehringer Ingelheim International GmbH $427.49 04/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781684
Principal investigator 1 Boehringer Ingelheim International GmbH $174.80 04/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781686
Principal investigator 1 Boehringer Ingelheim International GmbH $43.50 04/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781688
Principal investigator 1 Eli Lilly and Company $1,810.12 04/23/2025 Non-covered Recipient Entity
THE TEXAS LIVER INSTITUTE
A PHASE 1, MULTICENTER, PARALLEL-DESIGN, SINGLE-DOSE, OPEN-LABEL STUDY OF LEPODISIRAN IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1187891104
Principal investigator 1 Ipsen Bioscience Inc. $10,710.55 04/23/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546537
Principal investigator 1 Madrigal Pharmaceuticals $6,219.72 04/23/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 04/23/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184189153
Principal investigator 1 PTC Therapeutics, Inc. $365.52 04/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN No dispute reported 06/30/2026 1249093341
Principal investigator 1 Amgen Inc. $1,622,855.23 04/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment No dispute reported 06/30/2026 1246639107
Principal investigator 1 AstraZeneca UK Limited $153,975.12 04/16/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 No dispute reported 06/30/2026 1185547141
Principal investigator 1 Ipsen Bioscience Inc. $5,941.35 04/15/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 04/15/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183462
Principal investigator 1 GlaxoSmithKline, LLC. $425.25 04/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163098
Principal investigator 1 Boehringer Ingelheim International GmbH $146.24 04/09/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781919
Principal investigator 1 Boehringer Ingelheim International GmbH $125.58 04/09/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781921
Principal investigator 1 Boehringer Ingelheim International GmbH $222.06 04/09/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781923
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 04/09/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781925
Principal investigator 1 GlaxoSmithKline, LLC. $5,129.73 04/08/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166819
Principal investigator 1 Ipsen Bioscience Inc. $535.45 04/08/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546531
Principal investigator 1 Ipsen Bioscience Inc. $2,326.55 04/08/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546533
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781894
Principal investigator 1 Boehringer Ingelheim International GmbH $64.02 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781896
Principal investigator 1 Boehringer Ingelheim International GmbH $118.86 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781898
Principal investigator 1 Boehringer Ingelheim International GmbH $118.86 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781900
Principal investigator 1 Boehringer Ingelheim International GmbH $125.16 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781902
Principal investigator 1 Boehringer Ingelheim International GmbH $3,700.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781905
Principal investigator 1 Boehringer Ingelheim International GmbH $155.99 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781907
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781909
Principal investigator 1 Boehringer Ingelheim International GmbH $2,150.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781911
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781913
Principal investigator 1 Boehringer Ingelheim International GmbH $950.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781915
Principal investigator 1 Boehringer Ingelheim International GmbH $14,000.00 04/07/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) No dispute reported 06/30/2026 1220781917
Principal investigator 1 X4 Pharmaceuticals, Inc. $499.20 04/02/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function No dispute reported 06/30/2026 1253117157
Principal investigator 1 Ipsen Bioscience Inc. $1,070.90 04/01/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546521
Principal investigator 1 Ipsen Bioscience Inc. $9,405.95 04/01/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546523
Principal investigator 1 Ipsen Bioscience Inc. $738.65 04/01/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 04/01/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184180948
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 03/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781480
Principal investigator 1 Boehringer Ingelheim International GmbH $50.40 03/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781482
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 03/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781484
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 03/28/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781486
Principal investigator 1 Genentech, Inc. $8,006.00 03/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572768
Principal investigator 1 Genentech, Inc. $16,500.00 03/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION INC
CPET No dispute reported 06/30/2026 1211572771
Principal investigator 1 Madrigal Pharmaceuticals $13,351.00 03/27/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241414
Principal investigator 1 Madrigal Pharmaceuticals $525.00 03/27/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241417
Principal investigator 1 GlaxoSmithKline, LLC. $525.00 03/26/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA No dispute reported 06/30/2026 1192170041
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,496.27 03/26/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223277057
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781470
Principal investigator 1 Boehringer Ingelheim International GmbH $5,800.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781472
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781474
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781476
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781494
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781496
Principal investigator 1 Boehringer Ingelheim International GmbH $949.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781498
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781500
Principal investigator 1 Boehringer Ingelheim International GmbH $196.65 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781502
Principal investigator 1 Boehringer Ingelheim International GmbH $2.70 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781504
Principal investigator 1 Boehringer Ingelheim International GmbH $126.75 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781506
Principal investigator 1 Boehringer Ingelheim International GmbH $126.75 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781508
Principal investigator 1 Boehringer Ingelheim International GmbH $126.75 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781510
Principal investigator 1 Boehringer Ingelheim International GmbH $126.75 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781512
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781514
Principal investigator 1 Ipsen Bioscience Inc. $1,460.77 03/25/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546515
Principal investigator 1 Ipsen Bioscience Inc. $4,192.00 03/25/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546517
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,965.00 03/21/2025 Non-covered Recipient Entity
American Research Corporation
PoCP study in cirrhosis and portal hypertension No dispute reported 06/30/2026 1220818687
Principal investigator 1 GlaxoSmithKline, LLC. $16,969.60 03/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163103
Principal investigator 1 Ipsen Bioscience Inc. $2,605.50 03/19/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546511
Principal investigator 1 Ipsen Bioscience Inc. $1,674.00 03/19/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,337.90 03/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184174588
Principal investigator 1 Ipsen Bioscience Inc. $3,600.00 03/14/2025 Non-covered Recipient Entity
American Research Corporation
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546507
Principal investigator 1 Ipsen Bioscience Inc. $2,000.00 03/14/2025 Non-covered Recipient Entity
American Research Corporation
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546509
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,693.98 03/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185547139
Principal investigator 1 Ipsen Bioscience Inc. $742.50 03/11/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546503
Principal investigator 1 Ipsen Bioscience Inc. $931.50 03/11/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546505
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $425,099.91 03/08/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE AMERICAN RESEARCH CORPORATION
A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects No dispute reported 06/30/2026 1214124362
Principal investigator 1 Ipsen Pharma SAS $4,766.00 03/07/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306991
Principal investigator 1 Grifols Shared Services North America, Inc. $29,262.33 03/05/2025 Non-covered Recipient Entity
American Research Corporation
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 1244167776
Principal investigator 1 Ipsen Pharma SAS $1,766.90 03/05/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306807
Principal investigator 1 Ipsen Pharma SAS $514.80 03/05/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306809
Principal investigator 1 Ipsen Pharma SAS $766.00 03/05/2025 Non-covered Recipient Entity
Ruane Clinical Research Group, Inc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306989
Principal investigator 1 Ipsen Bioscience Inc. $1,460.77 03/04/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546499
Principal investigator 1 Ipsen Bioscience Inc. $7,092.70 03/04/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546501
Principal investigator 1 GlaxoSmithKline, LLC. $16,200.00 03/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA No dispute reported 06/30/2026 1192170026
Recipient Gilead Sciences, Inc. $25.00 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229200421
Recipient Gilead Sciences, Inc. $25.00 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229200430
Recipient Gilead Sciences, Inc. $49.99 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229200438
Recipient Gilead Sciences, Inc. $49.99 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229200446
Recipient Gilead Sciences, Inc. $14.70 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229201606
Recipient Gilead Sciences, Inc. $14.70 02/27/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229201615
Recipient Gilead Sciences, Inc. $127.53 02/26/2025 Covered Recipient Physician A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229200453
Principal investigator 1 Amgen Inc. $3,464.32 02/25/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment No dispute reported 06/30/2026 1246649259
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781488
Principal investigator 1 Boehringer Ingelheim International GmbH $5.49 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781490
Principal investigator 1 Boehringer Ingelheim International GmbH $10.50 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781492
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781516
Principal investigator 1 Boehringer Ingelheim International GmbH $183.21 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781518
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781520
Principal investigator 1 Boehringer Ingelheim International GmbH $4.05 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781522
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781524
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781526
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 02/25/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781528
Principal investigator 1 Ipsen Bioscience Inc. $2,461.12 02/25/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546493
Principal investigator 1 Ipsen Bioscience Inc. $2,313.25 02/25/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,377.45 02/25/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155390
Principal investigator 1 GlaxoSmithKline, LLC. $506.25 02/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192166454
Principal investigator 1 GlaxoSmithKline, LLC. $8,066.08 02/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,339.30 02/24/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275491
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783151
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783153
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783155
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783157
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783159
Principal investigator 1 Boehringer Ingelheim International GmbH $6,000.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783161
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783163
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 02/21/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects No dispute reported 06/30/2026 1220783165
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,878.18 02/20/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171126
Principal investigator 1 Ipsen Bioscience Inc. $931.50 02/20/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546491
Principal investigator 1 AstraZeneca AB $55,200.10 02/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 No dispute reported 06/30/2026 1185547147
Principal investigator 1 AstraZeneca UK Limited $222,393.50 02/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA No dispute reported 06/30/2026 1185547133
Principal investigator 1 AstraZeneca UK Limited $205,385.72 02/19/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA No dispute reported 06/30/2026 1185547145
Principal investigator 1 Ipsen Pharma SAS $88.62 02/19/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306803
Principal investigator 1 Ipsen Pharma SAS $2,116.80 02/19/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306805
Principal investigator 1 Eli Lilly and Company $488,989.00 02/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP INC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187876017
Principal investigator 1 Ipsen Bioscience Inc. $1,460.77 02/18/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546487
Principal investigator 1 Ipsen Bioscience Inc. $1,465.85 02/18/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,301.40 02/18/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154174
Principal investigator 1 Intercept Pharmaceuticals, Inc. $675.00 02/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171124
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,796.35 02/12/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants. No dispute reported 06/30/2026 1190303707
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,619.21 02/12/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223275201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,000.00 02/11/2025 Non-covered Recipient Entity
American Research Corporation
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis No dispute reported 06/30/2026 1220818689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,219.00 02/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152946
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,600.00 02/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/11/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275025
Principal investigator 1 Madrigal Pharmaceuticals $1,150.50 02/10/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239638
Principal investigator 1 AstraZeneca UK Limited $312,899.41 02/06/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
Phase I Single Dose,Non Randomised,Ope NLabel,Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics,Safety and Tolerability of Mitiperstat No dispute reported 06/30/2026 1185547135
Principal investigator 1 Ipsen Bioscience Inc. $1,996.22 02/05/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546483
Principal investigator 1 Ipsen Bioscience Inc. $7,092.70 02/05/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,662.65 02/05/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152432
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 02/03/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781468
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781370
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781372
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781374
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781378
Principal investigator 1 Boehringer Ingelheim International GmbH $292.95 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781380
Principal investigator 1 Boehringer Ingelheim International GmbH $85.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781384
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781386
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781392
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781394
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781396
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781398
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781408
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781414
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781416
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781422
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781424
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781428
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781430
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781432
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781436
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781442
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781448
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781452
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781454
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781456
Principal investigator 1 Boehringer Ingelheim International GmbH $2,898.00 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781460
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781462
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/30/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781466
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $560,621.48 01/30/2025 Non-covered Recipient Entity
American Research Corporation
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment No dispute reported 06/30/2026 1235999029
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/29/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781412
Principal investigator 1 Ipsen Bioscience Inc. $14,817.53 01/29/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546473
Principal investigator 1 Ipsen Bioscience Inc. $1,465.85 01/29/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546479
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $561,877.38 01/28/2025 Non-covered Recipient Entity
American Research Corporation
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment No dispute reported 06/30/2026 1235999031
Principal investigator 1 Gilead Sciences, Inc. $7,398.94 01/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION, INC.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203750
Principal investigator 1 GlaxoSmithKline, LLC. $6,442.92 01/28/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192166424
Principal investigator 1 Eli Lilly and Company $1,214.24 01/27/2025 Non-covered Recipient Entity
THE TEXAS LIVER INSTITUTE
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187891106
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781376
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781382
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781388
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781390
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781400
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781402
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781404
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781406
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781410
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781418
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781420
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781426
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781434
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781438
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781440
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781444
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781446
Principal investigator 1 Boehringer Ingelheim International GmbH $143.22 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781450
Principal investigator 1 Boehringer Ingelheim International GmbH $64.26 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781458
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220781464
Principal investigator 1 Boehringer Ingelheim International GmbH $648.00 01/23/2025 Non-covered Recipient Entity
Texas Liver Institute Ste 101
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220781478
Principal investigator 1 Madrigal Pharmaceuticals $3,788.46 01/23/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238594
Principal investigator 1 AstraZeneca UK Limited $15,350.00 01/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
a Phase I Single Dose Non Randomised OpenL abel Parallel Group Study to Investigate the Effect of Hepatic Impairment on the pharmacokinetics Safety, and Tolerability of Balcinrenone No dispute reported 06/30/2026 1185547149
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $430,104.90 01/22/2025 Non-covered Recipient Entity
American Research Corporation
A Phase 1, Multicenter, Open-label, Single -dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and those with Moderate, and Severe Hepatic Impairment No dispute reported 06/30/2026 1235999033
Principal investigator 1 GlaxoSmithKline, LLC. $34,370.85 01/22/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA No dispute reported 06/30/2026 1192170021
Principal investigator 1 Ipsen Pharma SAS $4,491.00 01/22/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184306801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,039.55 01/21/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149050
Principal investigator 1 Eli Lilly and Company $34,643.03 01/17/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORP INC
A PHASE 1, MULTICENTER, PARALLEL, SINGLE-DOSE, OPEN-LABEL, SINGLE-PERIOD STUDY OF LY3502970 IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1187876251
Principal investigator 1 Ipsen Bioscience Inc. $1,070.90 01/17/2025 Non-covered Recipient Entity
American Research Corporation
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546463
Principal investigator 1 Ipsen Bioscience Inc. $742.50 01/17/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546465
Principal investigator 1 Ipsen Bioscience Inc. $540.00 01/17/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546467
Principal investigator 1 Ipsen Bioscience Inc. $297.00 01/17/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546469
Principal investigator 1 Ipsen Bioscience Inc. $337.50 01/17/2025 Non-covered Recipient Entity
American Research Corporation
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546471
Principal investigator 1 AstraZeneca UK Limited $39,922.75 01/13/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Phase I Single-Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 No dispute reported 06/30/2026 1185547153
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,618.00 01/09/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS No dispute reported 06/30/2026 1235969821
Principal investigator 1 GlaxoSmithKline, LLC. $5,414.65 01/09/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166808
Principal investigator 1 Madrigal Pharmaceuticals $8,716.24 01/09/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.35 01/07/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184145782
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,217.78 01/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A Multicentre Randomised Double-blind Placebo-Controlled Phase 2b Study to Evaluate the Safety of ZibotentanDapagliflozin in Combination Compared to Zibotentan Monotherapy as well as ZibotentanDapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis No dispute reported 06/30/2026 1185547137
Principal investigator 1 Madrigal Pharmaceuticals $1,021.80 01/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237903
Principal investigator 1 Madrigal Pharmaceuticals $825.00 01/03/2025 Non-covered Recipient Entity
AMERICAN RESEARCH CORPORATION
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237915
Principal investigator 1 Deciphera Pharmaceuticals Inc. $249,905.29 01/02/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS No dispute reported 06/30/2026 1235969775
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,483.20 01/02/2025 Non-covered Recipient Entity
TEXAS LIVER INSTITUTE
A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS No dispute reported 06/30/2026 1235969779